Experimental drug trial seeks to tame long COVID's lingering misery
NCT ID NCT07108036
Summary
This study aims to test the safety and side effects of an experimental drug called Anktiva in people with Long COVID. Twenty adults with persistent symptoms like fatigue, brain fog, and shortness of breath for at least 60 days will receive up to two doses. Researchers will closely monitor participants for any health problems and track if their symptoms improve.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LONG COVID are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of California - San Francisco
San Francisco, California, 94110, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.